SCHEMBL1015677

SCHEMBL1015677

CCN(C(=O)CCCC(=O)Nc1ccc(Cl)cc1C(=O)O)c1cc(-c2ccc(F)cc2)ccc1C

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.44
ALDH1A1 P00352 2/20 0.44
GAA P10253 2/20 0.41
MAPT P10636 4/20 0.40
POLB P06746 2/20 0.40
HCAR2 Q8TDS4 2/20 0.40
SERPINE1 P05121 2/20 0.39
HSD17B10 Q99714 1/20 0.39
LTB4R2 Q9NPC1 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
TSHR P16473 1/20 0.38
LMNA P02545 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1016668 0.91 RXFP1 (0.40) KDM4EALDH1A1GAAMAPTPOLB
SCHEMBL1014871 0.87 SERPINE1 (0.51) KDM4EALDH1A1GAAMAPTPOLB
SCHEMBL1014912 0.87 MEN1 (0.42) KDM4EALDH1A1GAAMAPTSERPINE1
SCHEMBL1015814 0.87 LMNA (0.43) KDM4EALDH1A1GAAMAPTPOLB
SCHEMBL17530241 0.82 SERPINE1 (0.52) KDM4EALDH1A1GAAMAPTPOLB
SCHEMBL1013901 0.79 MAPT (0.41) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL1013863 0.79 SERPINE1 (0.44) KDM4EALDH1A1GAAMAPTPOLB
SCHEMBL1014811 0.79 ALDH1A1 (0.45) KDM4EALDH1A1GAAMAPTPOLB
SCHEMBL1014731 0.78 SERPINE1 (0.41) KDM4EALDH1A1GAAMAPTPOLB
SCHEMBL417503 0.75 MAPT (0.64) KDM4EALDH1A1GAAMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US claimed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US claimed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP claimed
EP-2990057-B1 PAI-1 INHIBITOR FOR USE IN ENHANCING THE ANTITUMOR EFFECT OF AN ANTITUMOR AGENT IN A PATIENT RENASCIENCE CO LTD (JP) 2019-03-20 EP disclosed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 KDM4E 4108/4885ALDH1A1 888/4885GAA 459/4885
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 KDM4E 4253/4885ALDH1A1 273/4885GAA 849/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 KDM4E 4348/4885ALDH1A1 177/4885GAA 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.